Our findings also align with clinical data from 12 different cancer types, including prostate cancer, in the Human Disease Blood Atlas database, which identified increased levels of FABP5, PRDX1, CD59 and CD73 in the blood plasma of cancer patients (Álvez et al., 2023). This evidence concerns the gene NT5E and cancer.